OTTAWA, May 1 (Reuters) – The Canadian health regulator said on Friday that it had approved Canada-based Apotex’s generic version of semaglutide, making it the second copycat version of Danish drugmaker Novo Nordisk’s blockbuster diabetes drug Ozempic authorized in the country.
(Reporting by Ismail Shakil and Ryan Patrick Jones; Editing by Caitlin Webber)
Comments